Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

作者：Roboz Gail J^*; Ritchie Ellen K; Curcio Tania; Samuel Michael; Provenzano Juliette; Segovia Javier; Christos Paul J; Mathew Susan; Allen Bard Sandra; Feldman Eric J

来源：Leukemia Research, 2011, 35(4): 522-525.

DOI：10.1016/j.leukres.2010.09.010

• Myelodysplastic syndrome
• MDS
• Arsenic
• Low-dose cytarabine

Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.

• 出版日期2011-4